Trials / Completed
CompletedNCT00394745
Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
A 12 Week Treatment, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Valsartan 160-320 mg With Regard to Effects on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate potential effects of valsartan on lipid subfractions and other parameters in lipid metabolism in patients with essential hypertension and metabolic syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valsartan |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2006-11-01
- Last updated
- 2017-02-24
Locations
2 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00394745. Inclusion in this directory is not an endorsement.